CompletedNCT05142709
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fudan University
- Principal Investigator
- Lvhua Wang, M.D.Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- Intervention
- Anti-PD-1 Immune Checkpoint Inhibitors(drug)
- Enrollment
- 1197 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (23)
- The 2nd affiliated hospital of Bengbu medical University, Bengbu, Anhui, China
- The 2nd people's hospital of Anhui province, Hefei, Anhui, China
- Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
- The 1st affiliated hospital of Xiamen University, Xiamen, Fujian, China
- Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, Guangdong, China
- The 4th affiliated hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- Anyang cancer hospital, Anyang, Henan, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Wuhan University Zhongnan hospital, Wuhan, Hubei, China
- Zhongnan University Xiangya Hospital, Changsha, Hunan, China
- Huai'an first hospital, Huai'an, Jiangsu, China
- Jiangsu cancer Hosipital, Nanjing, Jiangsu, China
- Nantong cancer hospital, Nantong, Jiangsu, China
- Yancheng the 3rd hospital, Yancheng, Jiangsu, China
- The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05142709 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc
See all trials for Squamous cell carcinoma of the esophagus →